Do analysts rate AIDX or MOBQ?

20/20 Biolabs currently has a consensus target price of $5.00, suggesting a potential upside of 986.01%. Given 20/20 Biolabs' stronger consensus rating and higher probable upside, research analysts plainly believe 20/20 Biolabs is more favorable than Mobiquity Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 20/20 Biolabs 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Mobiquity Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts recommend JOB or AIDX?

20/20 Biolabs has a consensus target price of $5.00, suggesting a potential upside of 986.01%. Given 20/20 Biolabs' stronger consensus rating and higher probable upside, analysts plainly believe 20/20 Biolabs is more favorable than GEE Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GEE Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 20/20 Biolabs 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings & valuation, JOB or AIDX?

20/20 Biolabs has lower revenue, but higher earnings than GEE Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GEE Group $87.98M 0.26 -$24.10M N/A N/A 20/20 Biolabs $1.84M 3.06 -$3.43M -$0.28 N/A

Do analysts rate SKYQ or AIDX?

20/20 Biolabs has a consensus target price of $5.00, indicating a potential upside of 986.01%. Given 20/20 Biolabs' stronger consensus rating and higher probable upside, analysts clearly believe 20/20 Biolabs is more favorable than Sky Quarry. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sky Quarry 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 20/20 Biolabs 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is SKYQ or AIDX more profitable?

20/20 Biolabs has a net margin of 0.00% compared to Sky Quarry's net margin of -97.65%. 20/20 Biolabs' return on equity of 0.00% beat Sky Quarry's return on equity. Company Net Margins Return on Equity Return on Assets Sky Quarry -97.65% -238.54% -53.73% 20/20 Biolabs N/A N/A N/A

Does the media refer more to SKYQ or AIDX?

In the previous week, Sky Quarry had 1 more articles in the media than 20/20 Biolabs. MarketBeat recorded 3 mentions for Sky Quarry and 2 mentions for 20/20 Biolabs. 20/20 Biolabs' average media sentiment score of 1.85 beat Sky Quarry's score of 1.12 indicating that 20/20 Biolabs is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sky Quarry 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive 20/20 Biolabs 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts recommend AIDX or PMEC?

20/20 Biolabs presently has a consensus target price of $5.00, indicating a potential upside of 986.01%. Given 20/20 Biolabs' stronger consensus rating and higher probable upside, equities analysts clearly believe 20/20 Biolabs is more favorable than Primech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 20/20 Biolabs 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Primech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, AIDX or PMEC?

Primech has higher revenue and earnings than 20/20 Biolabs. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio 20/20 Biolabs $1.84M 3.06 -$3.43M -$0.28 N/A Primech $74.35M 0.26 -$1.94M N/A N/A

Is AIDX or PMEC more profitable?

Company Net Margins Return on Equity Return on Assets 20/20 Biolabs N/A N/A N/A Primech N/A N/A N/A

Does the media refer more to AIDX or PMEC?

In the previous week, Primech had 1 more articles in the media than 20/20 Biolabs. MarketBeat recorded 3 mentions for Primech and 2 mentions for 20/20 Biolabs. 20/20 Biolabs' average media sentiment score of 1.85 beat Primech's score of 0.62 indicating that 20/20 Biolabs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 20/20 Biolabs 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Primech 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer RTB or AIDX?

20/20 Biolabs has a consensus price target of $5.00, indicating a potential upside of 986.01%. Given 20/20 Biolabs' stronger consensus rating and higher possible upside, analysts plainly believe 20/20 Biolabs is more favorable than RTB Digital, Inc. Common Stock. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RTB Digital, Inc. Common Stock 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 20/20 Biolabs 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is RTB or AIDX more profitable?

20/20 Biolabs has a net margin of 0.00% compared to RTB Digital, Inc. Common Stock's net margin of -165.69%. Company Net Margins Return on Equity Return on Assets RTB Digital, Inc. Common Stock -165.69% N/A -100.25% 20/20 Biolabs N/A N/A N/A

Does the media refer more to RTB or AIDX?

In the previous week, RTB Digital, Inc. Common Stock and RTB Digital, Inc. Common Stock both had 2 articles in the media. 20/20 Biolabs' average media sentiment score of 1.85 beat RTB Digital, Inc. Common Stock's score of 0.63 indicating that 20/20 Biolabs is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RTB Digital, Inc. Common Stock 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive 20/20 Biolabs 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

20/20 Biolabs (AIDX) Competitors

$0.46 -0.03 (-6.23%)

As of 09:39 AM Eastern

Compare

AIDX vs. MOBQ, JOB, SKYQ, PMEC, and RTB

Should you buy 20/20 Biolabs stock or one of its competitors? MarketBeat compares 20/20 Biolabs with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with 20/20 Biolabs include Mobiquity Technologies (MOBQ), GEE Group (JOB), Sky Quarry (SKYQ), Primech (PMEC), and RTB Digital, Inc. Common Stock (RTB). These companies are all part of the "business services" industry.

How does 20/20 Biolabs compare to Mobiquity Technologies?

20/20 Biolabs (NASDAQ:AIDX) and Mobiquity Technologies (NASDAQ:MOBQ) are both small-cap business services companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

14.2% of Mobiquity Technologies shares are held by institutional investors. 29.8% of 20/20 Biolabs shares are held by insiders. Comparatively, 24.5% of Mobiquity Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

20/20 Biolabs has higher revenue and earnings than Mobiquity Technologies. Mobiquity Technologies is trading at a lower price-to-earnings ratio than 20/20 Biolabs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
20/20 Biolabs	$1.84M	3.06	-$3.43M	-$0.28	N/A
Mobiquity Technologies	$1.24M	21.17	-$6.53M	-$0.48	N/A

20/20 Biolabs currently has a consensus target price of $5.00, suggesting a potential upside of 986.01%. Given 20/20 Biolabs' stronger consensus rating and higher probable upside, research analysts plainly believe 20/20 Biolabs is more favorable than Mobiquity Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
20/20 Biolabs	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Mobiquity Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, 20/20 Biolabs had 2 more articles in the media than Mobiquity Technologies. MarketBeat recorded 2 mentions for 20/20 Biolabs and 0 mentions for Mobiquity Technologies. 20/20 Biolabs' average media sentiment score of 1.85 beat Mobiquity Technologies' score of 0.00 indicating that 20/20 Biolabs is being referred to more favorably in the media.

Company	Overall Sentiment
20/20 Biolabs	Very Positive
Mobiquity Technologies	Neutral

20/20 Biolabs has a net margin of 0.00% compared to Mobiquity Technologies' net margin of -279.27%. 20/20 Biolabs' return on equity of 0.00% beat Mobiquity Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
20/20 Biolabs	N/A	N/A	N/A
Mobiquity Technologies	-279.27%	-212.32%	-90.57%

Summary

20/20 Biolabs beats Mobiquity Technologies on 12 of the 15 factors compared between the two stocks.

How does 20/20 Biolabs compare to GEE Group?

GEE Group (NYSE:JOB) and 20/20 Biolabs (NASDAQ:AIDX) are both small-cap business services companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends.

In the previous week, 20/20 Biolabs had 2 more articles in the media than GEE Group. MarketBeat recorded 2 mentions for 20/20 Biolabs and 0 mentions for GEE Group. 20/20 Biolabs' average media sentiment score of 1.85 beat GEE Group's score of 0.00 indicating that 20/20 Biolabs is being referred to more favorably in the news media.

Company	Overall Sentiment
GEE Group	Neutral
20/20 Biolabs	Very Positive

20/20 Biolabs has a consensus target price of $5.00, suggesting a potential upside of 986.01%. Given 20/20 Biolabs' stronger consensus rating and higher probable upside, analysts plainly believe 20/20 Biolabs is more favorable than GEE Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GEE Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
20/20 Biolabs	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

20/20 Biolabs has a net margin of 0.00% compared to GEE Group's net margin of -20.77%. 20/20 Biolabs' return on equity of 0.00% beat GEE Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GEE Group	-20.77%	-7.66%	-6.84%
20/20 Biolabs	N/A	N/A	N/A

20/20 Biolabs has lower revenue, but higher earnings than GEE Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GEE Group	$87.98M	0.26	-$24.10M	N/A	N/A
20/20 Biolabs	$1.84M	3.06	-$3.43M	-$0.28	N/A

30.4% of GEE Group shares are held by institutional investors. 17.0% of GEE Group shares are held by company insiders. Comparatively, 29.8% of 20/20 Biolabs shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

20/20 Biolabs beats GEE Group on 11 of the 14 factors compared between the two stocks.

How does 20/20 Biolabs compare to Sky Quarry?

Sky Quarry (NASDAQ:SKYQ) and 20/20 Biolabs (NASDAQ:AIDX) are both small-cap services companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.

In the previous week, Sky Quarry had 1 more articles in the media than 20/20 Biolabs. MarketBeat recorded 3 mentions for Sky Quarry and 2 mentions for 20/20 Biolabs. 20/20 Biolabs' average media sentiment score of 1.85 beat Sky Quarry's score of 1.12 indicating that 20/20 Biolabs is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sky Quarry	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
20/20 Biolabs	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

20/20 Biolabs has a consensus target price of $5.00, indicating a potential upside of 986.01%. Given 20/20 Biolabs' stronger consensus rating and higher probable upside, analysts clearly believe 20/20 Biolabs is more favorable than Sky Quarry.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sky Quarry	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
20/20 Biolabs	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

20/20 Biolabs has lower revenue, but higher earnings than Sky Quarry. 20/20 Biolabs is trading at a lower price-to-earnings ratio than Sky Quarry, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sky Quarry	$12.49M	1.49	-$12.20M	-$3.44	N/A
20/20 Biolabs	$1.84M	3.06	-$3.43M	-$0.28	N/A

20/20 Biolabs has a net margin of 0.00% compared to Sky Quarry's net margin of -97.65%. 20/20 Biolabs' return on equity of 0.00% beat Sky Quarry's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sky Quarry	-97.65%	-238.54%	-53.73%
20/20 Biolabs	N/A	N/A	N/A

Summary

20/20 Biolabs beats Sky Quarry on 10 of the 13 factors compared between the two stocks.

How does 20/20 Biolabs compare to Primech?

20/20 Biolabs (NASDAQ:AIDX) and Primech (NASDAQ:PMEC) are both small-cap business services companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk and valuation.

Primech has higher revenue and earnings than 20/20 Biolabs.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
20/20 Biolabs	$1.84M	3.06	-$3.43M	-$0.28	N/A
Primech	$74.35M	0.26	-$1.94M	N/A	N/A

88.1% of Primech shares are held by institutional investors. 29.8% of 20/20 Biolabs shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Primech had 1 more articles in the media than 20/20 Biolabs. MarketBeat recorded 3 mentions for Primech and 2 mentions for 20/20 Biolabs. 20/20 Biolabs' average media sentiment score of 1.85 beat Primech's score of 0.62 indicating that 20/20 Biolabs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
20/20 Biolabs	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Primech	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

20/20 Biolabs presently has a consensus target price of $5.00, indicating a potential upside of 986.01%. Given 20/20 Biolabs' stronger consensus rating and higher probable upside, equities analysts clearly believe 20/20 Biolabs is more favorable than Primech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
20/20 Biolabs	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Primech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
20/20 Biolabs	N/A	N/A	N/A
Primech	N/A	N/A	N/A

Summary

20/20 Biolabs beats Primech on 6 of the 10 factors compared between the two stocks.

How does 20/20 Biolabs compare to RTB Digital, Inc. Common Stock?

RTB Digital, Inc. Common Stock (NASDAQ:RTB) and 20/20 Biolabs (NASDAQ:AIDX) are both small-cap business services companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, media sentiment, valuation, earnings, institutional ownership, analyst recommendations and dividends.

20/20 Biolabs has a net margin of 0.00% compared to RTB Digital, Inc. Common Stock's net margin of -165.69%.

Company	Net Margins	Return on Equity	Return on Assets
RTB Digital, Inc. Common Stock	-165.69%	N/A	-100.25%
20/20 Biolabs	N/A	N/A	N/A

20/20 Biolabs has a consensus price target of $5.00, indicating a potential upside of 986.01%. Given 20/20 Biolabs' stronger consensus rating and higher possible upside, analysts plainly believe 20/20 Biolabs is more favorable than RTB Digital, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RTB Digital, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
20/20 Biolabs	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

20/20 Biolabs has lower revenue, but higher earnings than RTB Digital, Inc. Common Stock. 20/20 Biolabs is trading at a lower price-to-earnings ratio than RTB Digital, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RTB Digital, Inc. Common Stock	$11.13M	19.20	-$17.53M	-$28.90	N/A
20/20 Biolabs	$1.84M	3.06	-$3.43M	-$0.28	N/A

In the previous week, RTB Digital, Inc. Common Stock and RTB Digital, Inc. Common Stock both had 2 articles in the media. 20/20 Biolabs' average media sentiment score of 1.85 beat RTB Digital, Inc. Common Stock's score of 0.63 indicating that 20/20 Biolabs is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RTB Digital, Inc. Common Stock	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
20/20 Biolabs	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

17.4% of RTB Digital, Inc. Common Stock shares are held by institutional investors. 12.4% of RTB Digital, Inc. Common Stock shares are held by insiders. Comparatively, 29.8% of 20/20 Biolabs shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

20/20 Biolabs beats RTB Digital, Inc. Common Stock on 9 of the 13 factors compared between the two stocks.

Get 20/20 Biolabs News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AIDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AIDX vs. The Competition

Export

Metric	20/20 Biolabs	Services – Research, Development, Testing Labs Industry	Services Sector	NASDAQ Exchange
Market Cap	$5.64M	$7.90M	$17.16B	$12.20B
Dividend Yield	N/A	N/A	5.17%	9.80%
P/E Ratio	-1.64	N/A	19.27	23.63
Price / Sales	3.06	1.78	36.43	88.64
Price / Cash	N/A	N/A	79.87	46.67
Price / Book	N/A	0.06	12.02	6.08
Net Income	-$3.43M	-$15.16M	-$15.57M	$331.70M
7 Day Performance	-10.08%	-2.05%	-1.80%	-0.05%
1 Month Performance	-23.22%	-9.06%	24.19%	-2.63%
1 Year Performance	N/A	N/A	136.36%	13.91%

20/20 Biolabs Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AIDX 20/20 Biolabs	2.4117 of 5 stars	$0.46 -6.2%	$5.00 +986.0%	N/A	$5.64M	$1.84M	N/A	14	Positive News Gap Down
MOBQ Mobiquity Technologies	N/A	$0.85 -1.6%	N/A	-41.6%	$24.91M	$1.24M	N/A	10	Gap Down
JOB GEE Group	N/A	$0.22 +2.9%	N/A	-7.7%	$23.84M	$87.98M	N/A	310
SKYQ Sky Quarry	0.4465 of 5 stars	$4.44 +16.8%	N/A	-12.2%	$21.34M	$12.49M	N/A	N/A	Positive News Gap Up
PMEC Primech	0.3625 of 5 stars	$0.55 +5.5%	N/A	-66.0%	$21.09M	$74.35M	N/A	2,806

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AIDX) was last updated on 7/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

20/20 Biolabs (AIDX) Competitors

AIDX vs. MOBQ, JOB, SKYQ, PMEC, and RTB

How does 20/20 Biolabs compare to Mobiquity Technologies?

Summary

How does 20/20 Biolabs compare to GEE Group?

Summary

How does 20/20 Biolabs compare to Sky Quarry?

Summary

How does 20/20 Biolabs compare to Primech?

Summary

How does 20/20 Biolabs compare to RTB Digital, Inc. Common Stock?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AIDX vs. The Competition

20/20 Biolabs Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

20/20 Biolabs (AIDX) Competitors

AIDX vs. MOBQ, JOB, SKYQ, PMEC, and RTB

How does 20/20 Biolabs compare to Mobiquity Technologies?

Do insiders & institutionals have more ownership in AIDX or MOBQ?

Which has preferable valuation and earnings, AIDX or MOBQ?

Do analysts rate AIDX or MOBQ?

Does the media favor AIDX or MOBQ?

Is AIDX or MOBQ more profitable?

Summary

How does 20/20 Biolabs compare to GEE Group?

Does the media refer more to JOB or AIDX?

Do analysts recommend JOB or AIDX?

Is JOB or AIDX more profitable?

Which has preferable earnings & valuation, JOB or AIDX?

Do institutionals & insiders have more ownership in JOB or AIDX?

Summary

How does 20/20 Biolabs compare to Sky Quarry?

Does the media refer more to SKYQ or AIDX?

Do analysts rate SKYQ or AIDX?

Which has stronger valuation & earnings, SKYQ or AIDX?

Is SKYQ or AIDX more profitable?

Summary

How does 20/20 Biolabs compare to Primech?

Which has preferable earnings and valuation, AIDX or PMEC?

Do insiders & institutionals believe in AIDX or PMEC?

Does the media refer more to AIDX or PMEC?

Do analysts recommend AIDX or PMEC?

Is AIDX or PMEC more profitable?

Summary

How does 20/20 Biolabs compare to RTB Digital, Inc. Common Stock?

Is RTB or AIDX more profitable?

Do analysts prefer RTB or AIDX?

Which has higher earnings & valuation, RTB or AIDX?

Does the media refer more to RTB or AIDX?

Do institutionals and insiders believe in RTB or AIDX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AIDX vs. The Competition

20/20 Biolabs Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools